Pharmacovigilance is also known as Drug Safety, It
is the Pharmacological Science relating to the collection, detection,
assessment, monitoring and prevention of adverse effects with pharmaceutical
The theme of the conference is "
Safer Drugs to
Market by Analyzing Latest Developments in Pharmacovigilance, Drug Safety and
Risk Management", informed Dr. Srinubabu Gedela, Managing Director of OMICS
Pharmacovigilance and all drug safety issues are relevant
for everyone whose life is touched in any way by medical interventions,
informed Dr. Srinubabu Gedela.
Recently, its concerns have been widened to include
herbals, traditional and complementary medicines, blood products, biologicals,
medical devices and vaccines. Substandard medicines, medication errors, lack of
efficacy reports, use of medicines for indications that are not approved and
for which there is inadequate scientific basis, case reports of acute and chronic
poisoning, abuse and misuse of medicines are some of the concerns of the whole
world. Conference like this addresses issues and helps industry find out
solutions informed Anil of OMICS
The Curtain Raiser press conference was also addressed by
Dr. Malla Reddy, Prof Emiraturs of All India Council of Technical Education
; Dr. M. Venkata Reddy, Director, Hitech Institute of Advance
Pharmaceutical Sciences; Dr Ravi Kanneti, Manager, Dr. Reddys Laboratories
Ltd.; Mr S V Krishna Prasad, CEO & Director, Cito Healthcare (P) Ltd.
Speaking on the occasionDr. Malla Reddy said,
Pharmcovigilance is a very important subject. It is in its nascent stage in
India. Until sometime ago Hyderabad used to be the Bulk Drug Capital.
Similarly, we all though Hyderabad would also become a Hub for Clinical Trials.
But, unfortunately due to irresponsible communication and bad publicity, we
could never become. Samll countries like Singapore, Malaysia reaped rich
awards out of Clinical Trials.
Media misled people about Clinical Trials. There
could be few stray incident which were not very good for industry, but, due to
bad publicity, we have lost a great opportunity. If a lakh clinical
trials happen in America, not even 2000 Clinical Trials happen in India, he said.
He want government and media to create awareness about
Dr. Malla Reddy wanted Governments to
appoint qualified pharmacists in hospitals and drug stores to explain the
contents of the drug.
Dr. Venkat Reddy said every medicine is a useful
poision. It works well if taken in right does. If there is any variation, it
works adversely. It takes 12 to 15years before a new drug is introduced
in the market. For every drug to get evolved and accepted it needs so much time
for series of tests to prove its efficacy. And Pharma Companies spend
anywhere in the range of Rs 300 to 500 crore to develop and introduce a new
drug. From 1960 till now 150 drugs were taken back from the market due to
their adverse reactions. Due to which Rs 7500 core spent on developing these
drugs has gone down the drain, he observed.
Pharmacovigilance is just ten years old in this
country. 3 to 5 per cent of those who are hospitalized are due to adverse
reaction of the drug. People are not aware who to complain in such cases.
Media plays a vital role creating awareness. Let people come forward and
report such cases. Even we don't find prescription audit in India
Over the last couple of decades, advances in
biomedical science have generated more new and complex medicines to treat a
broader range of diseases and conditions than ever before. The number of people
taking medications has increased dramatically, and, as a result, governments,
patient groups and health advocates are demanding stronger regulatory practices
and procedures, to assure the safety of medicines before and after they reach
Hence, as the regulatory landscape continues to
evolve it is crucial that a professional keeps abreast of the changes impacting
the drug safety industry to ensure that their pharmacovigilance
strategies are robust and geared to compliance. In addition to this
effective risk management and minimisation efforts and comprehensive benefit:
risk analysis of drugs must lay the foundations for a strong drug safety
strategy. The 3rd
Edition of Pharmacovigilance is organised in
this light of background. Pharmacovigilance-2014 conference is being
collaborated with Society of Pharmacovigilance, India . This educational 3 day conference
will provide a unique platform for learning and networking.
Some of the subjects and issues that will be
deliberated during the meet include: Pharmacovigilance and its
Challenges; Role of Clinical Trials; Clinical Trials on Diseases; Adverse Drug
Reactions; Pharmacokinetics and Pharmacodynamics; Pharmacy Practices and its
Challenges; Risk Management: New Approaching Paradigm for Pharmacovigilance;
Clinical Research and Statistics; Strategies for Growth in Pharma Environment;
Good Pharmacovigilance Practice and Pharmacoepidemiology; Case Report in
Clinical Trials and others.
Indian Pharmaceutical industry is worth more than Rs.
90,000 crores and it is growing at the rate of 12 - 14% per annum.
India is the Global Clinical trial hub and there is simultaneous global
introduction of new medicines. Clinical data mining and signal detection
associated with pharmacovigilance technology contribute to potential benefits
in providing safe and secured drug administration and public health. In
the wake of Hyderabad attaining a centre place as a pharmaceutical hub, OMICS
International Conference and Exhibition on
Pharmacovigilance & Clinical Trials attains significance.
India is home for more than half a million qualified
doctors and 15,000 hospitals having bed strength of 6, 24,000 and it is the
fourth largest producer of pharmaceuticals in the world. According to various
estimates, Adverse Drug Reactions occur in 10-20% of hospital inpatients,
accounting for 2-6 % of all hospital admissions, and are among top 10 causes of
death in inpatients. Overall incidence of Adverse Drug Reaction (ADR) is about
6.7 % and 0.32 %. 15-20% of hospital budget may be spent dealing with fatal
drug complications. 30% to 60% of ADRs are preventable. More than 121 médecines have been withdrawn to
endure public safety for the past 40 years.
use of animal and human for the drug research in the name of Clinical trial is
equally contravercial where animals are subjected to risk for
testing the new drugs. Incomplete information is often provided for the patient
that volunteers for Clinical Trials. Keeping the national as well as global
pharmaceutical industry growth, OMICS Group International announces its 3rd
Conference and Exhibition on Pharmacovigilance & Clinical
Trials during October 27-29, 2014 at Hyderabad
International Convention Centre (HICC), Hyderabad, India with a
theme "Safer Drugs to Market by Analyzing Latest Developments in
Pharmacovigilance, Drug Safety and Risk Management".
OMICS Group International contributes to the
scientific community through its Open Access Initiative and OMICS Group
Conferences. OMICS Group hosts over 400 leading-edge peer reviewed Open Access
Journals which are supported by more than 30000 eminent Editorial Board
Members. OMICS Publishing Group journals enjoy the readership of 3.5 million
people and organize over 300 International Conferences annually all over the
world with the support of more than 1000 scientific associations. OMICS Group
Conferences conducts Scientific Conferences, symposia, workshops, trade shows,
exhibitions and world science congresses by bringing together people on a
single platform and thereby achieving its goal of widening the knowledge base
across the world.
Reference: Solus Media